CCNE1 and prostate carcinoma: Our result is in line with our studies showing that CAPE treatments downregulated cyclin E expression in human prostate carcinoma PC-3 and overexpression of NDRG1 in human glioma U87 MG cells blocked cyclin E expression [26,27].